,i #aaith ,,congress #b;d ,session ,h4 ,r4 #ajaej ,,in ,,the ,,house ,,of ,,representatives ,august #bg1 #bjbf,ms4 ,boebert 7for herself and ,mr4 ,van ,orden7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to provide a period of market exclusivity for botanical drugs1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,advancing ,botanical ,drug ,development ,act of #bjbf4 #b4 ,findings ,congress finds the following3 7#a7 ,chronic and age-related diseases are among the leading causes of disability1 impaired quality of life1 and health care spending in the ,united ,states4 7#b7 ,many chronic and age-related diseases involve multiple biological pathways and complex pathophysiology1 yet most currently approved therapies are designed to target a single molecular pathway4 7#c7 ,botanical drugs regulated by the ,food and ,drug ,administration 7in this section referred to as the ,,fda7 under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 may contain multiple naturally occurring active constituents capable of acting on multiple biological pathways simultaneously and safely4 7#d7 ,since the ,,fda established a regulatory pathway for botanical drugs in #bjjd1 only a limited number of botanical drugs have received approval1 despite significant scientific and therapeutic potential and the growing interest of patients in evidence-based1 ,,fda-approved treatment options derived from natural products4 7#e7 ,in addition to the costs associated with the clinical development of conventional synthetic drugs1 botanical drugs present unique scientific and manufacturing challenges arising from the natural variability of plant-derived raw materials1 including the need for extensive sourcing controls1 batch consistency testing1 constituent characterization1 and standardization processes to ensure safety1 quality1 and effectiveness4 ,these additional development burdens may increase costs and commercial uncertainty for sponsors seeking to bring innovative botanical therapies to market4 7#f7 ,as a result of these unique scientific1 manufacturing1 and regulatory challenges1 existing intellectual property and regulatory exclusivity frameworks may not provide sufficient incentives to support private investment in the research and development of innovative botanical drugs4 7#g7 ,congress has previously recognized that certain categories of complex medical products require tailored periods of regulatory exclusivity to encourage innovation and facilitate long-term investment in research and development4 7#h7 ,expanding incentives for the development of safe and effective botanical drugs may increase multi-target treatment options for patients suffering from multi-pathway1 chronic and age-related diseases while promoting biomedical innovation and economic growth in the ,united ,states4 7#i7 ,advances in computational biology1 artificial intelligence1 and systems pharmacology have created new opportunities to identify and develop innovative botanical drug combinations capable of addressing complex diseases through multi-pathway mechanisms of action4 7#aj7 ,it is in the public interest to encourage the development and approval of multi-target1 evidence-based1 ,,fda-regulated botanical drugs subject to the same standards of safety and effectiveness applicable to other drugs regulated by the ,,fda4 #c4 ,period of market exclusivity for botanical drugs ,section #eje7;c77#c77;,e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77#c77;,e77 is amended by adding at the end the following3 7vi7 7,i7 ,a botanical drug approved under subsection 7b77#a7 pursuant to an application submitted after the date of enactment of this clause shall be entitled to a #ab-year period during which no application submitted under subsection 7b77#b7 or 7j7 that references or relies upon such drug may become effective4 7,,ii7 ,in this clause1 the term botanical drug means a botanical drug subject to subsection 7a71 as determined by the ,secretary by regulation4 4